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ABSTRACT 
The incidence of neonatal Group B streptococcal (GBS) disease has significantly declined since 
the widespread implementation of prenatal screening of expectant mothers for urogenital and 
gastrointestinal tract GBS colonization. Screening methods have evolved from exclusively 
culture-based approaches to more rapid and highly sensitive molecular methods. We chose to 
evaluate the performance of four commercially available GBS molecular tests for detection of 
GBS colonization using 299 antepartum rectal-vaginal specimens submitted to our laboratory for 
routine GBS screening. In 97% of instances, there was agreement between all three systems. 
When testing 1, 6, and 12 samples simultaneously, all methods performed comparably, but the 
ARIES
® 
GBS assay required the least total hands-on time and the illumigene
 
Group B 
Streptococcus assay required the most hands-on time.  
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1. Introduction 
Streptococcus agalactiae (Group B Streptococcus [GBS]) is a Gram-positive, catalase-
negative, facultative anaerobe that is known to harmlessly colonize the urogenital and 
gastrointestinal tracts of humans. In susceptible hosts (e.g., neonates, pregnant women, and those 
with chronic medical conditions), GBS is a versatile opportunistic pathogen that is capable of 
causing a variety of diseases, including urinary tract, respiratory, wound, and central nervous 
system infections (Spellerberg and Brandt, 2015). GBS is the leading cause of neonatal 
morbidity and mortality in the U.S. and, according to the Centers for Disease Control and 
Prevention (CDC), approximately 10-30% of pregnant women are colonized with this bacterium 
(CDC, 2010; Schuchat, 1999); in our patient population, the GBS colonization rate is 
approximately 20%. 
Determination of maternal GBS colonization status prior to labor and delivery is 
paramount for guiding appropriate intrapartum antimicrobial prophylaxis (CDC, 2010). 
Currently, recommendations state that all pregnant women, except those who have had GBS 
bacteriuria during their current pregnancy and those who have previously delivered a child who 
developed early-onset GBS disease, should be screened for rectovaginal GBS colonization. For 
the exceptions noted, intrapartum antibiotic prophylaxis without rectovaginal screening is 
indicated since GBS bacteriuria diagnosed at any time during the current pregnancy and 
instances of early-onset GBS infection in previously born neonates are known risk factors for 
GBS infections in current pregnancies (Verani et al., 2010; Schrag et al., 2002; Faxelius et al., 
1988). Because of nearly universal implementation of maternal prenatal GBS screening in the 
U.S., the incidence of neonatal GBS infections has dramatically declined (e.g., ~80% reduction 
in early-onset infections). Effective GBS surveillance strategies entail collection of rectal-vaginal 
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specimens from pregnant women between 35 and 37 weeks of gestation (CDC, 2010; ACOG, 
2011). Swab specimens are subsequently analyzed for GBS by cultivation-based and/or 
molecular methods. Despite its relatively high sensitivity, selective culture is slow, requiring up 
to 48 hours for result reporting (Nomura et al., 2006); however, culture remains indispensable in 
cases where an isolate is required for antimicrobial susceptibility testing (e.g., when an alternate 
antibiotic must be used for patients who are allergic to β-lactam antibiotics). Although this slow 
turnaround time is tolerable for routine surveillance, it is unsatisfactory when a result is needed 
much sooner, such as when testing must be performed during active labor. In addition, with the 
assistance of automated molecular GBS testing platforms, numerous samples can be tested 
simultaneously, allowing laboratory scientists to perform other tasks. 
Currently, there are several molecular GBS testing platforms that are commercially 
available as either in vitro diagnostic products or as research-use-only systems, as classified by 
the FDA. These assays employ nucleic acid amplification or nucleic acid probes for detecting 
GBS-specific genetic markers in either enrichment broths and/or directly from patient specimens. 
Depending on the needs of the laboratory, systems are able to perform single tests if test volumes 
are relatively low or multiple tests simultaneously if test volumes are high. In addition, the 
hands-on time (HoT) of these assays vary from long to short, the latter accounted for by the 
almost total involvement of automation in the testing process. The HoT required for these tests is 
important since most laboratories are staffed by scientists who are required to carry out 
numerous tasks throughout their work shifts. In laboratories that process large volumes of GBS 
specimens, test systems that offer relatively hands-free usage and provide high sample 
throughput often help mitigate the effects of laboratory staffing shortages and increased 
workload burdens. However, in small laboratories, systems that require a longer HoT may be 
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acceptable especially if the test volume is low and the physical space required to accommodate 
large instrumentation is not readily available. The aim of this study was to compare the 
performance characteristics, the HoT, and the total turnaround time (TAT; HoT plus automation 
time [AuT]) of four commercially available GBS molecular diagnostic tests: the BD MAX™ 
GBS assay, the ARIES
®
 GBS assay, the illumigene
®
 Group B Streptococcus assay, and the 
Xpert
®
 GBS LB assay using remnant, de-identified, antepartum rectal-vaginal specimens that 
were submitted to our laboratory for routine GBS screening. Table 1 shows a comparison of 
various aspects of these test systems.    
 
2. Materials and methods 
2.1 Specimens. Two hundred ninety-nine remnant antepartum rectal-vaginal swab enrichment 
broths were de-identified according to institutional review board-approved methods and were 
enrolled in this study. Rectal-vaginal swabs (BBL
®
 CultureSwab™ Liquid Stuart, double swab; 
BD) were collected from women ranging in age from 16 – 42 years (median, 27 years) who were 
between 35 and 37 weeks of gestation.  
 
2.2 Standard-of-care (SOC) analysis. Rectal-vaginal swabs were broken off into Lim broth 
(BD), and inoculated broths were incubated for 18 – 24 h at 35C in ambient air. Following 
incubation, 15-µl aliquots of well-mixed enrichment broths were tested by the BD MAX™ GBS 
Assay (BD) according to the manufacturer’s instructions. External positive and negative controls 
were assayed once per day. 
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2.3 Comparator testing. Following SOC analysis, all remnant GBS enrichment broths were 
stored at 4C and were tested by all comparator assays within 36 hours of placement in storage 
and in accordance with the manufacturers’ specifications. Aliquots of remnant enrichment broths 
were tested by the ARIES
® 
GBS Assay, the illumigene
®
 Group B Streptococcus Assay, and the 
Xpert
® 
GBS LB assay. Prior to comparator testing, broths were vortexed for 5 s to create a 
homogenous suspension. Testing was repeated once if invalid results were obtained in the initial 
test.  
For ARIES
® 
GBS testing, 200-µl aliquots were removed and pipetted into the sample 
chambers of ARIES
® 
GBS Assay cassettes. Loaded cassettes were analyzed by the ARIES
® 
System, which automates nucleic acid extraction and purification, as well as real-time PCR-
based detection of GBS target nucleic acids.  
For illumigene
®
 Group B Streptococcus Assay testing, 50-µl aliquots of well-mixed 
broths were added to illumigene heat treatment tubes containing 200 µl of illumigene control 
reagent. Subsequently, samples were vortexed for 10 s and incubated for 10 min at 95ºC. Fifty-
microliter aliquots of heat-treated samples were next added to illumigene reaction buffer tubes 
and were vortexed for 10 s. Fifty-microliter aliquots of the resulting solution were pipetted into 
test and control chambers of illumigene test devices. Following inoculation, test devices were 
inserted into the illumipro-10 instrument for nucleic acid amplification and detection. 
For Xpert
®
 GBS LB assay testing, broth-saturated swabs were used to inoculate test 
cartridges, which were subsequently analyzed using a GeneXpert XVI instrument (Cepheid). 
Like the BD MAX and ARIES systems, the GeneXpert system fully automates all steps of GBS 
nucleic acid extraction, purification, and target detection. 
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External positive and negative quality control samples were assayed in accordance with 
manufacturer recommendations. 
 
2.4 Discrepant result resolution. Discrepant molecular GBS test results were arbitrated by 
bacterial culture and bidirectional nucleotide sequencing. For bacterial culture, 10-µl aliquots of 
GBS enrichment broth were inoculated onto nonselective sheep blood agar plates (TSA w/ 5% 
sheep blood; Remel, Lenexa, KS), which were subsequently incubated for 24 h at 35C in 5% 
CO2. Suspicious colonies (e.g., small, translucent colonies surrounded by narrow zones of β-
hemolysis) were identified using the PathoDX
®
 Strep Grouping latex agglutination kit (Remel, 
Lenexa, KS). For nucleotide sequencing, total nucleic acids were extracted from enrichment 
broths using the NucliSENS
®
 easyMag
® 
system (bioMérieux, Durham, NC). PCR using primers 
targeting GBS genomic sequences distinct from those targeted by the molecular assays 
compared in this study (Table 1) was subsequently performed and amplicons were sequenced 
by capillary electrophoresis on an Applied Biosystems 3130xl genetic analyzer (Applied 
Biosystems, Foster City, CA). Resulting nucleotide sequences were analyzed using the 3130xl 
Data Collection software (v3.1.1) and Sequencing Analysis software (v5.4). Sequences that 
were at least 200 bases in length, had a Phred quality score of ≥20 for at least 90% of the bases, 
and contained fewer than 5% ambiguous base calls were subsequently analyzed using BLAST 
(Altschul et al., 1997). Acceptable matches to BLAST reference sequences were those with 
>95% query coverage and identity, and an E-Value <10-30 when compared to the reference 
sequence.  
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2.5 Hands-on-Time (HoT) and total turnaround time (TAT) analyses. For HoT and total 
TAT, the assay set-up, run initiation, analytical, and post-analytical times were measured using a 
stopwatch. HoT was evaluated for individual samples as well as when 6 and 12 samples were run 
simultaneously. Because the illumigene

 system can only accommodate a maximum of 10 
samples at once, 2 runs were performed in order to accommodate 12-sample testing. The data 
from these runs were combined. In order to calculate the total TAT, the HoT and the time 
samples were being analyzed by automated instrumentation (AuT) were added together. Data 
represent the average of two independent observations of testing performed by a single 
technologist.  
 
2.6 Statistical analysis. Positive and negative percent agreement (PPA and NPA, respectively), 
in addition to overall percent agreement, along with confidence intervals, were calculated for 
each comparator assay using the BD MAX™ GBS Assay result as the non-reference standard. 
Calculations were performed according to U.S. Department of Health and Human Services 
guidelines (U.S. Food and Drug Administration, 2017). 
 
3. Results 
Of the 299 specimens included in this study, 147 (49.2%) were positive by all four 
platforms while 144 (48.2%) were negative by all. The percent GBS-positive, and Positive and 
Negative Percent Agreement results for each assay (as well as results of temporal aspect 
comparisons) are shown in Table 2. One invalid result was obtained by the ARIES
®
 method; 
however upon retesting, a valid negative result was obtained. Nine of 299 (3%) specimens 
yielded discrepancies between methods. Resolution of discordant results is shown in Table 3.  
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The total HoT for performance of single samples was less than 5 minutes (range, 
00:01:55 – 00:03:32 [h:min:sec]) for all assays. For a single sample, the ARIES® and Xpert 
assays both had HoT of 00:01:55, and the BD MAX and illumigene assays had HoT of 00:03:05 
and 00:03:32. Results for assay runs of 6 and 12 samples are shown in Table 2. 
The result TATs varied slightly for each assay when 1, 6, and 12 samples were run, but 
the overall TATs compared between methods ranged from less than 01:12:00 (h:min:sec) for the 
illumigene platform to approximately 2 h for both the ARIES
®
 and BD MAX systems. None of 
the systems were interfaced but the time to print and enter results into the Laboratory 
Information System was measured at 4.2 minutes for 12 specimens. Results of total TAT 
analysis are compared in Table 2. 
 
4. Discussion 
The introduction of molecular methods such as real-time PCR and LAMP technologies 
has revolutionized the detection of GBS colonization. In addition to rapid result turnaround, the 
sensitivity of these methods is higher than that of culture alone. In a previous study that 
compared the performance of the BD MAX™ GBS Assay, the illumigene® Group B 
Streptococcus Assay, and the BD GeneOhm™ StrepB, all three assays demonstrated higher 
sensitivity than culture, which ranged from 67% to 73% (Couturier et al., 2014). A similar study 
that compared the BD MAX™ GBS Assay, the illumigene® Group B Streptococcus Assay, and 
the AmpliVue
®
 GBS Assay (Quidel) found that these assays were between 37.3% and 46.4% 
more sensitive than culture for the detection of GBS colonization (Miller et al., 2015). In both of 
these studies, the agreement in sensitivities between platforms was high: 97.1% to 98.4% for 
Couturier et al. and 90.9% to 100% for Miller et al.  
In this study, we sought to evaluate the performance characteristics, including the PPA 
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and NPA, and compare the temporal aspects of assay performance, including the HoT and total 
TAT, of four commercially available GBS molecular diagnostic tests for the detection of GBS 
colonization in antepartum women. To do so, we enrolled 299 remnant Lim enrichment broths 
originating in our laboratory from SOC antepartum GBS screening tests in a study that compared 
our in-house method, the BD MAX
™ 
GBS assay, to three comparator methods, the Luminex 
ARIES
®
 GBS research-use-only assay, the Meridian Biosciences illumigene
®
 Group B 
Streptococcus assay, and the Cepheid Xpert
® 
GBS LB assay. 
The ARIES
® 
GBS assay required the least total HoT for testing 1, 6, and 12 samples 
while the illumigene
 
Group B Streptococcus assay required the most HoT when testing 1, 6, and 
12 samples. The fastest total TAT was seen with the Xpert

 GBS LB assay, which required less 
than 01:12:00 minutes from sample manipulation to result reporting for 1, 6, and 12 samples. 
The slowest total TAT was seen with the BD MAX™ GBS assay when 12 samples were tested 
(time, 02:10:26). All systems tested in this comparison study produced actionable results much 
sooner than traditional, culture-based methods, which supporting the notion that molecular GBS 
testing is an ideal solution for GBS surveillance in modern clinical microbiology laboratories. 
The analytical results from the four molecular methods was very similar and in 
agreement for 291 (97%) of the specimens tested. Overall, each of these broth-enrichment-based 
methods agreed with the culture and sequencing results 98% or more of the time, which is 
consistent with the information provided in each of the products’ package inserts. In addition, 
discrepant resolution by bacterial culture and nucleotide sequencing detected GBS in two 
samples that the non-gold standard reference (BD MAX™ GBS) declared negative but one or 
more of the comparator methods declared positive, validating the importance of arbitration. As 
newer methods for the detection of maternal GBS colonization become available, similar studies 
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will be required in order to determine which system or systems fit with a laboratory’s staffing 
and workflow requirements and other diagnostic testing needs. In addition, studies comparing the 
efficacy of current and future systems for the detection of GBS directly from clinical specimens 
are also needed.  
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TABLE LEGENDS 
Table 1. Comparison of the GBS molecular assays evaluated in this study. 
 
Table 2. Performance characteristics of the GBS molecular assays evaluated in this study. 
 
Table 3. Results of discordant analysis for discrepant samples. 
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Table 1 
Test Company Technology Target 
Regulatory 
Status 
Approved 
specimen 
type(s) 
Sample 
to 
answer? 
Reported 
approximate 
assay 
turnaround 
time 
Instrumentation 
and test 
capacity per 
instrument 
BD MAX™ 
GBS Assay 
Becton 
Dickinson, 
Sparks, MD 
Real-time 
PCR using 
Scorpions
® 
probes, 
qualitative 
cfb gene, 
124-bp 
amplicon  
In vitro 
diagnostic 
Lim Broth 
culture of 
vaginal-
rectal swab 
specimens 
from 
antepartum 
pregnant 
women, 
incubated 
> 18 hrs 
Yes <3 hrs 
BD MAX™ 
System; 24 
ARIES
®
 GBS 
Assay 
Luminex 
Corporation, 
Austin, TX 
Real-time 
PCR using 
MultiCode
®
-
RTx 
chemistry, 
qualitative 
Genomic 
region 
downstream 
from the cfb 
gene 
In vitro 
diagnostic
a
 
Lim Broth 
culture of 
vaginal-
rectal swab 
specimens 
from 
antepartum 
pregnant 
women, 
incubated 
18-24 hrs 
Yes <2 hrs 
ARIES
®
 
Systems; 6 and 
12 
illumigene
®
 
Group B 
Streptococcus 
assay 
Meridian 
Bioscience, 
Inc., 
Cincinnati, 
OH 
Loop-
mediated 
isothermal 
DNA 
amplification 
213-bp 
genomic 
region 
In vitro 
diagnostic 
Lim, 
TransVag, 
or Carrot 
Broth 
culture of 
No <1 hr illumipro-10; 10 
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(LAMP), 
qualitative 
vaginal-
rectal swab 
specimens 
from 
antepartum 
pregnant 
women, 
incubated 
18-24 hrs 
Xpert® GBS 
LB assay 
Cepheid 
Inc., 
Sunnyvale, 
CA 
Real-time 
PCR using 
fluorogenic 
probe 
detection, 
qualitative 
Genomic 
region 
adjacent to 
the cfb gene 
In vitro 
diagnostic 
Lim Broth 
culture of 
vaginal-
rectal swab 
specimens 
from 
antepartum 
pregnant 
women, 
incubated 
18-24 hrs 
Yes 35-55 min 
GeneXpert 
Systems; 1, 2, 4, 
16, 48, and 80 
a
Test was Research Use Only (RUO) at the time of this study. 
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Table 2 
 
a
Positive Percent Agreement 
b
Negative Percent Agreement 
c
Hands-on Time 
d
Turnaround Time  
e
Standard of care method, used as comparator for this study 
 
 
 
    HoT
c
 (h:min:sec) Total TAT
d
 (h:min:sec) 
Assay 
GBS-Positive 
Samples (%) 
PPA
a
 (95% 
CI) 
NPA
b
 (95% 
CI) 
1 
specimen 
6 
specimens 
12 
specimens 
1 specimen 
6 
specimens 
12 
specimens 
ARIES
®
 GBS 
151/299 
(50.5%) 
98.7%  
(94.9% - 
99.7%) 
98.0%  
(94.1% - 
99.3%) 
00:01:55 00:04:45 00:08:42 01:56:43 01:59:49 02:04:06 
BD MAX™ 
GBS
e
 
150/299 
(50.2%) 
n/a n/a 00:03:05 00:10:22 00:19:07 01:52:16 02:00:31 02:10:26 
Illumigene
®
 GBS 149/299 
(49.6%) 
98.0%  
(94.1% - 
99.3%) 
97.3%  
(93.2% - 
99.0%) 
00:03:32 00:11:41 00:18:25 00:53:32 01:01:41 02:03:23 
Xpert
®
 GBS LB 
151/299 
(50.5%) 
99.3%  
(95.5% - 
99.9%) 
98.7%  
(94.9% - 
99.7%) 
00:01:55 00:07:25 00:14:00 00:56:59 01:02:44 01:02:44 
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Table 3 
BD MAX™ GBS ARIES® GBS Illumigene® GBS Xpert® GBS LB Adjudicated Resulta 
Negative Negative Positive Negative Negative 
Negative Negative Positive Negative Negative 
Negative Positive Negative Negative Negative 
Negative Positive Positive Negative Positive 
Negative Negative Negative Positive Negative 
Negative Positive Positive Positive Positive 
Positive Negative Negative Negative Positive 
Positive Positive Negative Positive Positive 
Positive Positive Negative Positive Positive 
a
Discordant results were adjudicated by culture and PCR with bidirectional sequencing. 
 
BD MAX™ GBS ARIES® GBS Illumigene® GBS Xpert® GBS LB Adjudicated Resulta 
- - + - - 
- - + - - 
- + - - - 
- + + - + 
- - - + - 
- + + + + 
+ - - - + 
+ + - + + 
+ + - + + 
a
Discordant results were adjudicated by culture and PCR with bidirectional sequencing. 
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